A Phase 1/2 interventional study of AG-120 and Azacitidine in Leukemia, Myeloid, Acute, sponsored by Celgene. Active, not recruiting at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 50th largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2016, is one of 23 in phase 1/2, reaches primary completion later than 1 of the 90 other live ones, and was the 69th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 133 · Phase 3 31 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 211 interventional studies. Of the 100 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 214 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 9 (25%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2016, is one of 4 in phase 1/2, and was the 22nd registered.
Bristol-Myers Squibb’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
25 of the studies testing azacitidine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT06783790Institute of Hematology & Blood Diseases Hospital, ChinaAvapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | 2026-12 |
| NCT06066905Guangdong Provincial People's HospitalA Study of Chidamide With AZA in MRD Positive AML After Transplant | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, from their registry updates:
Among Bristol-Myers Squibb’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
The purpose of this study are
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AG-120 · Drug: Azacitidine
Drug: Azacitidine · Drug: AG-221
Drug: Azacitidine
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)
Dose-limiting toxicities (DLTs) are defined as an event that constitute a change from baseline irrespective of outcome and determined by the investigator to be related to treatment. The DLT-evaluable participants were defined as participants who took at least 1 dose of study drug in the Phase 1b Dose-Finding Stage and either had a DLT during Cycle 1 (regardless of amount of study drug exposure), or had no DLT and completed at least 75% of AG-120 or AG-221 doses (21 out of 28 days) and a minimum of 5 doses of AZA, at least 50% of the planned combination doses for AG-120 or AG-221 and AZA administered together (in the same day for 4 out of 7 days) in the first 28 days from C1D1, and were also considered by the Clinical Study Team to have sufficient safety data available to conclude that a DLT did not occur during Cycle 1.
Time frame: From first dose to 28 days after first dose
The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
Time frame: From first dose to 28 days after last dose (up to approximately 13 months)
Overall Response Rate: Phase 2 (Randomized Stage)
The percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Time frame: From first dose up to approximately 26 months
Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage)
Percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Time frame: From first dose up to approximately 13 months
Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)
The percent of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL). CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.
Time frame: From first dose up to approximately 13 months
Event-free Survival (EFS): Phase 2 (Randomized Stage)
Event-Free Survival is the time from date of randomization to the date of documented morphologic relapse, progression, or death from any cause, whichever occurs first. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.
Time frame: From randomization to the date of documented relapse, progression, or death due to any cause, whichever occurs first (up to approximately 26 months)
The Number of Participants Experiencing Adverse Events: Phase 2 (Randomized Stage)
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
Time frame: From first dose to 28 days after last dose (up to approximately 26 months)
Complete Remission Rate: Phase 2 (Randomized Stage)
The percent of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment.
Time frame: From first dose up to approximately 26 months
Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)
The percent of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10\^9/L for participants starting with \> 20 X and an increase from \< 20 X 10\^9/L to \> 20 X 10\^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase \> 0.5 X 10\^9/L.
Time frame: From first dose up to approximately 26 months
Duration of Response: Phase 2 (Randomized Stage)
The time from first documented CR/CRi/CRp/PR/MLFS to documented morphologic relapse, progression, or death due to any cause, whichever occurred first. CR and MLFS are defined as \<5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with \>50% decrease in BM blasts to 5%-25%. Relapse is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. Progression is defined as \> 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease.
Time frame: From first dose up to approximately 26 months
Time to Response: Phase 2 (Randomized Stage)
Time from first dose of study drug to first documented MLFS/CR/CRi/CRp/PR according to modified IWG AML response criteria. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
Time frame: From first dose to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 26 months)
Overall Survival: Phase 2 (Randomized Stage)
Overall survival (OS) is defined as time from randomization to death due to any cause.
Time frame: From randomization to date of death (up to approximately 26 months)
One Year Survival Rate: Phase 2 (Randomized Stage)
The percent of participants alive at 1 year from randomization
Time frame: From randomization to 1 year after randomization
AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 1B (Expansion Stage)
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.
Time frame: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Cmax- Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data
Time frame: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Tmax- Time of Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Time frame: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.
Time frame: Pre-dose, 2, 3, 4, 6, and 8 hours post dose (± 10 minutes) on day 1 of cycle 2
AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours, calculated using the linear trapezoid rule.
Time frame: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Time frame: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Time frame: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Change From Baseline in Health-related Quality-of-Life Domain Scores of the EORTC QLQ-C30: Phase 2 (Randomized Stage)
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. EORTC QLQ-C30 is assessed prior to dosing and prior to interaction with study personnel.
Time frame: Baseline and Day 1 Cycle 5
Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
Time frame: Baseline and Day 1 Cycle 5
Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)
The European Quality of Life 5D-5L (EQ-5D-5L) instrument has a respondent's self-rated today's health scale which is recorded on a VAS with endpoints labeled "the best health you can imagine" and "the worst health you can imagine." The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of QoL. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
Time frame: Baseline and Day 1 Cycle 5
Sponsor Derived CR: Phase 2 (Randomized Stage)
The number of participants with Morphologic Complete Remission (CR) based on laboratory data. CR is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment.
Time frame: From first dose to end of study
Sponsor Derived CR and CRh: Phase 2 (Randomized Phase)
The number of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.
Time frame: From first dose to end of study
Time to Sponsor Derived CR and CRh: Phase 2 (Randomized Phase)
Time from first dose of study drug to first documented CR/CRh. Morphologic Complete Remission (CR) is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. Morphologic complete remission with partial hematologic recovery (CRh) is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL).
Time frame: From first dose to end of study
Duration of Sponsor Derived CR/CRh: Phase 2 (Randomized Stage)
Time from first documented CR/CRh to documented morphologic relapse, PD, or death due to any cause, whichever occurred first. Participants without morphologic relapse, PD, or death due to any cause were censored at the date of the last response assessment. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression (PD) is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.
Time frame: From first dose to end of study
| Milestone | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 7 | 16 | 68 | 33 |
| Completed | 3 | 3 | 7 | 16 | 68 | 32 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 7 | 16 | 68 | 32 |
| Completed | 1 | 1 | 4 | 3 | 21 | 1 |
| Not completed | 2 | 2 | 3 | 13 | 47 | 31 |
| Withdrew: Adverse event | 0 | 0 | 1 | 3 | 5 | 2 |
| Withdrew: Progressive disease | 1 | 1 | 0 | 0 | 8 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 1 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 | 5 | 5 |
| Withdrew: Transition to commercially available treatment | 0 | 1 | 1 | 1 | 1 | 2 |
| Withdrew: Disease relapse | 0 | 0 | 0 | 3 | 6 | 1 |
| Withdrew: Allogeneic hsct | 1 | 0 | 0 | 1 | 4 | 1 |
| Withdrew: Other reasons | 0 | 0 | 0 | 1 | 3 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 12 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 0 | 0 | 1 | 0 |
Dose-limiting toxicities (DLTs) are defined as an event that constitute a change from baseline irrespective of outcome and determined by the investigator to be related to treatment. The DLT-evaluable participants were defined as participants who took at least 1 dose of study drug in the Phase 1b Dose-Finding Stage and either had a DLT during Cycle 1 (regardless of amount of study drug exposure), or had no DLT and completed at least 75% of AG-120 or AG-221 doses (21 out of 28 days) and a minimum of 5 doses of AZA, at least 50% of the planned combination doses for AG-120 or AG-221 and AZA administered together (in the same day for 4 out of 7 days) in the first 28 days from C1D1, and were also considered by the Clinical Study Team to have sufficient safety data available to conclude that a DLT did not occur during Cycle 1.
| Participants | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA |
|---|---|---|---|
| The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage) | 0 | 0 | 0 |
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
| Participants | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA |
|---|---|---|---|---|
| Participants with at Least One TEAE | 3 | 3 | 7 | 16 |
| Participants with at Least One TEAE Related to Study Drug(s) | 3 | 3 | 7 | 16 |
| Participants with at Least One Grade 3-4 TEAE | 3 | 3 | 7 | 15 |
| Participants with at least One Grade 3-4 TEAE Related to Study Drug(s) | 2 | 2 | 4 | 10 |
| Participants with at Least One Grade 5 TEAE | 0 | 1 | 1 | 2 |
| Participants with at Least One Grade 5 TEAE Related to Study Drug(s) | 0 | 0 | 0 | 0 |
| Participants with at Least One Serious TEAE | 3 | 2 | 4 | 11 |
| Participants with at Least One Serious TEAE Related to Study Drug(s) | 0 | 1 | 1 | 5 |
| Participants with at Least One TEAE Leading to Discontinuation of Study Drug(s) | 1 | 0 | 1 | 4 |
| Participants with at Least One Study Drug Related TEAE Leading to Discontinuation of Study Drug | 0 | 0 | 0 | 1 |
| Participants with at Least One TEAE Leading to Dose Reduction of Study Drug(s) | 1 | 1 | 2 | 5 |
| Participants with at Least One TEAE Leading to Dose Interruption of Study Drug(s) | 3 | 3 | 2 | 11 |
| Participants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose Reduction | 0 | 1 | 1 | 5 |
| Participants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose Interruption | 1 | 2 | 2 | 8 |
The percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
| Percent of Participants | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Overall Response Rate: Phase 2 (Randomized Stage) | 73.5 (61.4 to 83.5) | 36.4 (20.4 to 54.9) |
Percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
| Percent of Participants | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA |
|---|---|---|---|---|
| Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage) | 66.7 (9.4 to 99.2) | 66.7 (9.4 to 99.2) | 100 (59.0 to 100) | 68.8 (41.3 to 89.0) |
The percent of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL). CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.
| Percent of Participants | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA |
|---|---|---|---|---|
| Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage) | 66.7 (9.4 to 99.2) | 66.7 (9.4 to 99.2) | 71.4 (29.0 to 96.3) | 62.5 (35.4 to 84.8) |
Event-Free Survival is the time from date of randomization to the date of documented morphologic relapse, progression, or death from any cause, whichever occurs first. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.
| Months | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Event-free Survival (EFS): Phase 2 (Randomized Stage) | 15.9 (13.0 to NA) | 11.9 (8.2 to 15.5) |
The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.
| Participants | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Participants with at Least One TEAE | 68 | 32 |
| Participants with at Least One TEAE Related to Study Drug(s) | 62 | 26 |
| Participants with at Least One Grade 3-4 TEAE | 68 | 31 |
| Participants with at least One Grade 3-4 TEAE Related to Study Drug(s) | 50 | 20 |
| Participants with at Least One Grade 5 TEAE | 15 | 2 |
| Participants with at Least One Grade 5 TEAE Related to Study Drug(s) | 0 | 0 |
| Participants with at Least One Serious TEAE | 64 | 25 |
| Participants with at Least One Serious TEAE Related to Study Drug(s) | 29 | 14 |
The percent of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment.
| Percent of Participants | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Complete Remission Rate: Phase 2 (Randomized Stage) | 54.4 (41.9 to 66.5) | 12.1 (3.4 to 28.2) |
The percent of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10\^9/L for participants starting with \> 20 X and an increase from \< 20 X 10\^9/L to \> 20 X 10\^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase \> 0.5 X 10\^9/L.
| Percent of Participants | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage) | 70.6 (58.3 to 81.0) | 57.6 (39.2 to 74.5) |
The time from first documented CR/CRi/CRp/PR/MLFS to documented morphologic relapse, progression, or death due to any cause, whichever occurred first. CR and MLFS are defined as \<5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with \>50% decrease in BM blasts to 5%-25%. Relapse is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. Progression is defined as \> 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease.
| Months | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Duration of Response: Phase 2 (Randomized Stage) | 24.1 (10.0 to NA) | 9.9 (5.5 to 13.6) |
Time from first dose of study drug to first documented MLFS/CR/CRi/CRp/PR according to modified IWG AML response criteria. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).
| Months | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Time to Response: Phase 2 (Randomized Stage) | 3.05 ± 2.551 | 3.42 ± 1.720 |
Overall survival (OS) is defined as time from randomization to death due to any cause.
| Months | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Overall Survival: Phase 2 (Randomized Stage) | 22.0 (14.6 to NA) | 22.3 (11.9 to NA) |
The percent of participants alive at 1 year from randomization
| Percent of Participants | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| One Year Survival Rate: Phase 2 (Randomized Stage) | 72.2 (59.6 to 81.5) | 69.6 (49.6 to 82.9) |
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.
| (h*ng/mL) | Phase 1b Expansion Stage: AG-120 (500mg) + AZA |
|---|---|
| CYCLE 1 DAY 1 | 31952.4465 ± 16008.00412 |
| CYCLE 2 DAY 1 | 44291.5504 ± 18806.17037 |
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data
| (ng/mL) | Phase 1b Expansion Stage: AG-120 (500mg) + AZA |
|---|---|
| CYCLE 1 DAY 1 | 6058.0 ± 2750.97 |
| CYCLE 2 DAY 1 | 6340.7 ± 3191.00 |
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
| (h) | Phase 1b Expansion Stage: AG-120 (500mg) + AZA |
|---|---|
| CYCLE 1 DAY 1 | 3.0000 (0.500 to 8.067) |
| CYCLE 2 DAY 1 | 2.5000 (0.500 to 7.850) |
Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.
| (h*ng/mL) | Phase 2 Randomized Stage: AG-221 (100mg) + AZA |
|---|---|
| AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage) | 100302.8231 ± 61286.98611 |
AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours, calculated using the linear trapezoid rule.
| (h*ng/mL) | Phase 2 Randomized Stage: AG-221 (100mg) + AZA |
|---|---|
| AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage) | 285864.2637 ± 190300.31922 |
Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
| (ng/mL) | Phase 2 Randomized Stage: AG-221 (100mg) + AZA |
|---|---|
| Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage) | 15965.0 ± 9663.47 |
Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
| (h) | Phase 2 Randomized Stage: AG-221 (100mg) + AZA |
|---|---|
| Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage) | 2.5333 (0.000 to 23.917) |
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. EORTC QLQ-C30 is assessed prior to dosing and prior to interaction with study personnel.
| Score on a scale | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Global QoL | 12.2 ± 27.36 | 4.9 ± 27.33 |
| Physical functioning | 1.9 ± 20.6 | 6.7 ± 23.57 |
| Role functioning | -0.6 ± 29.57 | 1.0 ± 30.88 |
| Cognitive functioning | -4.8 ± 26.00 | 4.9 ± 25.53 |
| Emotional functioning | 7.7 ± 24.42 | 8.8 ± 18.51 |
| Social functioning | -6.5 ± 29.52 | 6.9 ± 34.89 |
| Fatigue | -17.5 ± 33.05 | -8.5 ± 31.06 |
| Nausea and vomiting | -6.0 ± 29.47 | 1.0 ± 16.11 |
| Pain | -13.1 ± 33.13 | -4.9 ± 30.48 |
| Dyspnea | -27.4 ± 35.20 | -9.8 ± 28.30 |
| Insomnia | -6.0 ± 25.75 | -13.7 ± 26.51 |
| Appetite loss | -7.1 ± 42.90 | -5.9 ± 35.81 |
| Constipation | 6.0 ± 32.78 | -9.8 ± 22.87 |
| Diarrhea | -7.1 ± 31.89 | -5.9 ± 29.43 |
| Financial difficulties | 8.3 ± 19.51 | -2.0 ± 34.30 |
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
| Score on a scale | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage) | 0.04 ± 0.216 | 0.02 ± 0.211 |
The European Quality of Life 5D-5L (EQ-5D-5L) instrument has a respondent's self-rated today's health scale which is recorded on a VAS with endpoints labeled "the best health you can imagine" and "the worst health you can imagine." The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of QoL. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
| Score on a scale | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|
| Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage) | 13.00 ± 26.166 | 1.65 ± 27.897 |
The number of participants with Morphologic Complete Remission (CR) based on laboratory data. CR is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment.
Results for this outcome have not been posted.
The number of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.
Results for this outcome have not been posted.
Time from first dose of study drug to first documented CR/CRh. Morphologic Complete Remission (CR) is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. Morphologic complete remission with partial hematologic recovery (CRh) is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL).
Results for this outcome have not been posted.
Time from first documented CR/CRh to documented morphologic relapse, PD, or death due to any cause, whichever occurred first. Participants without morphologic relapse, PD, or death due to any cause were censored at the date of the last response assessment. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression (PD) is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.
Results for this outcome have not been posted.
Collected over From first dose up to approximately 26 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Phase 1b Expansion Stage: AG-120 (500mg) + AZA | 6/16 (37.5%) | 11/16 (68.8%) | 16/16 (100%) |
| Phase 2 Randomized Stage: AG-221 (100mg) + AZA | 29/68 (42.6%) | 64/68 (94.1%) | 67/68 (98.5%) |
| Phase 2 Randomized Stage: AZA Monotherapy | 14/33 (42.4%) | 25/32 (78.1%) | 32/32 (100%) |
| Event | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/3 | 1/3 | 1/7 | 7/16 | 26/68 | 8/32 |
| ColitisGastrointestinal disorders | 1/3 | 0/3 | 0/7 | 1/16 | 1/68 | 0/32 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/3 | 0/3 | 0/7 | 0/16 | 0/68 | 0/32 |
| PyrexiaGeneral disorders | 0/3 | 1/3 | 0/7 | 3/16 | 4/68 | 2/32 |
| Clostridium difficile colitisInfections and infestations | 1/3 | 0/3 | 0/7 | 0/16 | 0/68 | 0/32 |
| Lung infectionInfections and infestations | 0/3 | 1/3 | 0/7 | 2/16 | 7/68 | 3/32 |
| PneumoniaInfections and infestations | 1/3 | 1/3 | 2/7 | 0/16 | 7/68 | 5/32 |
| Blood bilirubin increasedInvestigations | 1/3 | 1/3 | 0/7 | 0/16 | 3/68 | 0/32 |
| Mental status changesPsychiatric disorders | 0/3 | 1/3 | 0/7 | 0/16 | 0/68 | 0/32 |
| EmbolismVascular disorders | 0/3 | 1/3 | 0/7 | 0/16 | 0/68 | 0/32 |
| Event | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/3 | 3/3 | 3/7 | 7/16 | 35/68 | 15/32 |
| Abdominal painGastrointestinal disorders | 3/3 | 1/3 | 0/7 | 4/16 | 12/68 | 5/32 |
| VomitingGastrointestinal disorders | 1/3 | 3/3 | 1/7 | 9/16 | 33/68 | 11/32 |
| Blood bilirubin increasedInvestigations | 1/3 | 3/3 | 1/7 | 1/16 | 19/68 | 1/32 |
| NauseaGastrointestinal disorders | 2/3 | 2/3 | 6/7 | 8/16 | 47/68 | 12/32 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/3 | 2/3 | 5/7 | 7/16 | 40/68 | 14/32 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 2/3 | 5/7 | 9/16 | 29/68 | 9/32 |
| FatigueGeneral disorders | 1/3 | 1/3 | 5/7 | 4/16 | 19/68 | 8/32 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 2/3 | 2/7 | 3/16 | 31/68 | 9/32 |
| ConstipationGastrointestinal disorders | 2/3 | 1/3 | 4/7 | 7/16 | 31/68 | 15/32 |
| Age, Customized(Participants) | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy | Total |
|---|---|---|---|---|---|---|---|
| < 65 | 0 | 1 | 0 | 3 | 7 | 1 | 12 |
| >= 65-< 75 | 1 | 2 | 2 | 6 | 22 | 14 | 47 |
| >= 75 | 2 | 0 | 5 | 7 | 39 | 18 | 71 |
| Sex: Female, Male(Participants) | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 3 | 9 | 36 | 11 | 63 |
| Male | 1 | 1 | 4 | 7 | 32 | 22 | 67 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| Not Hispanic or Latino | 3 | 3 | 6 | 14 | 51 | 26 | 103 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 16 | 6 | 24 |
| Race (NIH/OMB)(Participants) | Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA | Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA | Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA | Phase 1b Expansion Stage: AG-120 (500mg) + AZA | Phase 2 Randomized Stage: AG-221 (100mg) + AZA | Phase 2 Randomized Stage: AZA Monotherapy | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 0 | 5 | 1 | 8 |
| White | 2 | 2 | 7 | 13 | 49 | 24 | 97 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 13 | 7 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Aug 2018, 25 months.
Results were first posted in Nov 2022, 4 years 3 months after primary completion.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 25 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine